Please log in to see the full text of this API!

Ado-Trastuzumab Emtansine

  • Synonyms: Trastuzumab emtansine; T-DM1
  • ATC: L01XC14
  • Use: Lorem 
  • Chemical name: Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam
  • Formula: Lorem ipsum dolor sit amet,
  • MW:148.5 kDa
  • CAS-RN:1018448-65-1

Substance Classes

Synthesis Path










Substances Referenced in Synthesis Path

CAS-RN Formula Chemical Name CAS Index Name
860706-16-7 C3H6O2S 3-mercaptopropanoic acid -
138148-59-1 C4H8O2S2 3-(methyldithio)-propanoic acid -
6066-82-6 C4H5NO3 N-hydroxy-succinimide -
3913-67-5 C4H9NO2 N-methyl-L-alanine -
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem

Trade Names

Country Trade Name Vendor Annotation
EU Lorem Lorem
USA Lorem Lorem
(wfm = withdrawn from market)

Formulations

  • Loremipsumdolorsitamet,consetetursadipscingelitr,seddiamnonumyeirmodtemporinviduntut

References

    • Chari, R. J. V. et al.,''Antibody-Drug Conjugate: An Emerging Concept in Cancer Therap.'', Angew. Chem. Int. Ed., (2014) 53(15), 3796-3827.
    • Lambert, J. M.; Chari, R. J. V., ''Ado-Trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer'', J. Med. Chem., (2014) 57(15), 3796-3827.
    • US 9 999 999 (Immunogen Inc.; 22.10.2013; USA-prior. 08.10.2003; 29.10.2007).
    • US 9 999 999 (Immunogen Inc.; 07.01.2014; USA-prior. 03.06.2009; 03.06.2010).
    • US 9 999 999 (Immunogen Inc.; 01.04.2014; USA-prior. 10.10.2003; 08.10.2004; 29.10.2007).
  • Analogs and intermediates:

    • Widdison, W. C. et al., J. Med. Chem., (2006) 49, 4392-4408.
  • Trastuzumab (Herceptin):

    • US 9 999 999 (Genentech; 13.10.1998; USA-prior. 14.06.1991; 15.06.1992; 21.08.1992).
  • DM1:

    • US 9 999 999 (Immunogen Inc.; 04.05.1993; USA-prior. 25.10.1989; 13.07.1992).
    • US 9 999 999 (Immunogen Inc.; 25.12.2001; USA-prior. 18.08.2000).
  • Ansamitocins by fermentation:

    • US 9 999 999 (Takeda; 24.04.1979; JP-prior. 01.04.1977; 31.03.1977).
Cookie-Einstellungen